These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15049429)

  • 1. Use of fusion proteins and procaryotic display systems for delivery of HIV-1 antigens: development of novel vaccines for HIV-1 infection.
    De Berardinis P; Sartorius R; Caivano A; Mascolo D; Domingo GJ; Del Pozzo G; Gaubin M; Perham RN; Piatier-Tonneau D; Guardiola J
    Curr HIV Res; 2003 Oct; 1(4):441-6. PubMed ID: 15049429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New recombinant vaccines based on the use of prokaryotic antigen-display systems.
    De Berardinis P; Haigwood NL
    Expert Rev Vaccines; 2004 Dec; 3(6):673-9. PubMed ID: 15606352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of specific T-helper and cytolytic responses to epitopes displayed on a virus-like protein scaffold derived from the pyruvate dehydrogenase multienzyme complex.
    Domingo GJ; Caivano A; Sartorius R; Barba P; Bäckström M; Piatier-Tonneau D; Guardiola J; De Berardinis P; Perham RN
    Vaccine; 2003 Mar; 21(13-14):1502-9. PubMed ID: 12615447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses.
    De Berardinis P; Sartorius R; Fanutti C; Perham RN; Del Pozzo G; Guardiola J
    Nat Biotechnol; 2000 Aug; 18(8):873-6. PubMed ID: 10932158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential live vaccines for HIV.
    Burnett MS; Wang N; Hofmann M; Barrie Kitto G
    Vaccine; 2000 Nov; 19(7-8):735-42. PubMed ID: 11115694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
    Berzofsky JA
    Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filamentous fusion phage cloning vectors for the study of epitopes and design of vaccines.
    Parmley SF; Smith GP
    Adv Exp Med Biol; 1989; 251():215-8. PubMed ID: 2481962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate.
    Larijani MS; Sadat SM; Bolhassani A; Pouriayevali MH; Bahramali G; Ramezani A
    Curr HIV Res; 2018; 16(5):322-337. PubMed ID: 30605062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1.
    Xu W; Liu J; Gong W; Chen J; Zhu S; Zhang L
    Vaccine; 2011 Mar; 29(15):2672-8. PubMed ID: 21324344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multi-epitope polypeptide approach in HIV-1 vaccine development.
    Cano CA
    Genet Anal; 1999 Nov; 15(3-5):149-53. PubMed ID: 10596755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments.
    Gaubin M; Fanutti C; Mishal Z; Durrbach A; De Berardinis P; Sartorius R; Del Pozzo G; Guardiola J; Perham RN; Piatier-Tonneau D
    DNA Cell Biol; 2003 Jan; 22(1):11-8. PubMed ID: 12590733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple display of peptides and proteins on a macromolecular scaffold derived from a multienzyme complex.
    Domingo GJ; Orru' S; Perham RN
    J Mol Biol; 2001 Jan; 305(2):259-67. PubMed ID: 11124904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.
    Wagner R; Deml L; Schirmbeck R; Reimann J; Wolf H
    Behring Inst Mitt; 1994 Dec; (95):23-34. PubMed ID: 7755506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.
    Thomson SA; Jaramillo AB; Shoobridge M; Dunstan KJ; Everett B; Ranasinghe C; Kent SJ; Gao K; Medveckzy J; Ffrench RA; Ramshaw IA
    Vaccine; 2005 Sep; 23(38):4647-57. PubMed ID: 15964105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.
    Okazaki T; Terabe M; Catanzaro AT; Pendleton CD; Yarchoan R; Berzofsky JA
    J Virol; 2006 Nov; 80(21):10645-51. PubMed ID: 16920824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semi-allogeneic vaccines for patients with cancer and AIDS.
    Newton DA; Acierno PM; Brescia FJ; Brown EA; Gattoni-Celli S
    J Immunother; 2002; 25(4):334-41. PubMed ID: 12142556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenicity of HIV-derived T helper determinants in the context of carrier recombinant proteins: effect on T helper cell repertoire selection.
    Manca F; De Berardinis P; Fenoglio D; Ombra MN; Li Pira G; Saverino D; Autiero M; Lozzi L; Bracci L; Guardiola J
    Eur J Immunol; 1996 Oct; 26(10):2461-9. PubMed ID: 8898961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.